UY37113A - Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento - Google Patents

Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Info

Publication number
UY37113A
UY37113A UY0001037113A UY37113A UY37113A UY 37113 A UY37113 A UY 37113A UY 0001037113 A UY0001037113 A UY 0001037113A UY 37113 A UY37113 A UY 37113A UY 37113 A UY37113 A UY 37113A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
treatment
stratification
compositions
Prior art date
Application number
UY0001037113A
Other languages
English (en)
Inventor
Martin Lange Dr
Antje Margret Wengner Dra
Ulrike Sack Dra
Heidi Greulich
Matthew Meyerson
De Waal Luc
Monica Schenone
Alex Burgin
A Lewis Timothy
Xiaoyun Wu
Philip Lienau Dr
Knut Eis Dr
Original Assignee
Dana Farber Cancer Inst Inc
Broad Inst Inc
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Broad Inst Inc, Bayer Pharma AG filed Critical Dana Farber Cancer Inst Inc
Publication of UY37113A publication Critical patent/UY37113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuestos mejorados, especialmente métodos para identificar pacientes que padecen de cáncer usando biomarcadores (por ejemplo, PDE3A, SLFN12 y/o CREB3L1) que están correlacionados con la sensibilidad al fármaco, y para someter la población de pacientes estratificados al tratamiento correspondiente con un agente de la invención (por ejemplo, los compuestos 1-6 descriptos en la presente).
UY0001037113A 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento UY37113A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291935P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
UY37113A true UY37113A (es) 2017-08-31

Family

ID=58009797

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037113A UY37113A (es) 2016-02-05 2017-02-03 Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento

Country Status (9)

Country Link
US (2) US10966986B2 (es)
EP (1) EP3411037B1 (es)
JP (1) JP7148403B2 (es)
CN (2) CN108883112B (es)
AR (1) AR107529A1 (es)
CA (2) CA3013402C (es)
TW (1) TW201733591A (es)
UY (1) UY37113A (es)
WO (1) WO2017134231A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334404B1 (en) * 2015-08-13 2024-09-18 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a and slfn12
US10966986B2 (en) * 2016-02-05 2021-04-06 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN110831599B (zh) * 2017-02-03 2023-03-28 布罗德研究所股份有限公司 用于癌症治疗的化合物、组合物和方法
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
US11897867B2 (en) 2017-08-04 2024-02-13 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer
JP7104588B2 (ja) * 2017-09-01 2022-07-21 大塚製薬株式会社 ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤
JP7313614B2 (ja) * 2018-04-16 2023-07-25 学校法人順天堂 骨髄増殖性腫瘍の診断
WO2020157236A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Pyridyl substituted dihydrooxadiazinones
WO2020157199A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
CN110894529A (zh) * 2019-12-16 2020-03-20 新乡医学院 一种与结直肠癌早期诊断相关的环状rna标志物、检测引物、试剂盒及其应用
CN113176408B (zh) * 2021-06-02 2022-10-11 四川大学华西医院 一种甲状腺癌预后情况判断的方法
WO2023105119A1 (en) 2021-12-07 2023-06-15 Sartar Therapeutics Oy Synergistic compositions for use in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
US5856480A (en) * 1994-11-11 1999-01-05 Nippon Soda Co., Ltd. Optically active compound
WO2007038792A2 (en) * 2005-09-28 2007-04-05 H. Lee Moffitt Cancer Center Individualized cancer treatments
EP1960551A2 (en) * 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
WO2015077565A1 (en) * 2013-11-22 2015-05-28 Board Of Regents, The University Of Texas System Treating cancers with drugs targeting creb3l1
EP3334404B1 (en) 2015-08-13 2024-09-18 The Broad Institute, Inc. Compositions and methods for cancer expressing pde3a and slfn12
US10966986B2 (en) 2016-02-05 2021-04-06 Bayer Pharma Aktiengesellschaft Compounds, compositions and methods for cancer patient stratification and cancer treatment
CN110831599B (zh) * 2017-02-03 2023-03-28 布罗德研究所股份有限公司 用于癌症治疗的化合物、组合物和方法

Also Published As

Publication number Publication date
EP3411037B1 (en) 2021-10-20
AR107529A1 (es) 2018-05-09
CA3234176A1 (en) 2017-08-10
US12053476B2 (en) 2024-08-06
CN108883112B (zh) 2022-07-26
CN114601837A (zh) 2022-06-10
US20210236504A1 (en) 2021-08-05
JP2019508404A (ja) 2019-03-28
WO2017134231A1 (en) 2017-08-10
CN108883112A (zh) 2018-11-23
CA3013402A1 (en) 2017-08-10
JP7148403B2 (ja) 2022-10-05
US20190365770A1 (en) 2019-12-05
EP3411037A1 (en) 2018-12-12
TW201733591A (zh) 2017-10-01
CA3013402C (en) 2024-05-28
US10966986B2 (en) 2021-04-06

Similar Documents

Publication Publication Date Title
UY37113A (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
CL2017003103A1 (es) Compuestos de heteroarilo para la inhibición de cinasa
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
CO2018002568A2 (es) Acetamida tienotriazolodiazepinas y usos de las mismas
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
BR112017022281A2 (pt) métodos para tratar câncer
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230601